Aids activists say gilead put profits over patients — and misled congress about an hiv pill
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Last May, Gilead Sciences (GILD) chief executive Daniel O’Day testified before Congress that a revised version of a best-selling HIV pill was a “brand new medicine” and that the company was
“absolutely not” aware it was safer than an older version during the early stages of development. Yet a recently filed lawsuit offers details that purportedly contradict his remarks and, in
the process, raises questions about the extent to which Gilead may have deliberately delayed bringing a new treatment to market in order to milk sales of an older, lucrative franchise.
O’Day’s comments were made at a high-profile hearing about an HIV treatment and prevention drug called Truvada, although his assertions came in response to questions about an updated pill
called Descovy, which Gilead hopes will replace Truvada as a blockbuster seller. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK
THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this
story subscribe to STAT+. Subscribe